ATOS - ATOSSA THERAPEUTICS, INC.
IEX Last Trade
1.005
-0.015 -1.493%
Share volume: 0
Last Updated: Thu 26 Dec 2024 03:28:45 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
3.82%
PREVIOUS CLOSE
CHG
CHG%
$1.02
-0.02
-1.47%
Fundamental analysis
22%
Profitability
18%
Dept financing
3%
Liquidity
50%
Performance
25%
Performance
5 Days
6.88%
1 Month
-19.53%
3 Months
-25.90%
6 Months
0 0%
1 Year
32.09%
2 Year
99.57%
Key data
Stock price
$1.00
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.82 - $2.31
52 WEEK CHANGE
$14.14
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Steven C. Quay
Region: US
Website: atossatherapeutics.com
Employees: 8
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: atossatherapeutics.com
Employees: 8
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Atossa Therapeutics, Inc. focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxefen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized patients.
Recent news